BioCentury | Dec 5, 2011
Company News

Cellmed management update

Cellmed Research GmbH , Krems, Austria Business: Biomanufacturing, Supply/Service Hired: Karl Krista as CEO WIR Staff...
BioCentury | Mar 15, 2010
Company News

Biocompatibles, Celsion, Cortius B.V., Glycostem Therapeutics, ISA Pharmaceuticals, IQ Corp. B.V., Percuros B.V., Biomedical Materials, Center for Translational

...progenitor cells. Erasmus will work with University Medical Center Utrecht (UMCU), Biocompatibles and the company's CellMed...
BioCentury | Feb 22, 2010
Clinical News

CM-3: Phase I started

...Biocompatibles' CellMed AG unit began a double-blind, placebo-controlled, German Phase I trial to evaluate single ascending...
BioCentury | Dec 14, 2009
Clinical News

CM-3: Phase I start

...Next month, Biocompatibles' CellMed unit will begin a Phase I trial. AstraZeneca plc (LSE:AZN; NYSE:AZN, London...
BioCentury | Jan 14, 2008
Clinical News

Doxorubicin Drug Eluting Bead regulatory update

...The EC granted Orphan Drug designation for doxorubicin hydrochloride drug eluting beads from CellMed AG, a...
BioCentury | Jan 14, 2008
Clinical News

Irinotecan Drug Eluting Bead regulatory update

...The EC granted Orphan Drug designation for irinotecan hydrochloride drug eluting beads from CellMed AG, a...
BioCentury | Apr 22, 2002
Emerging Company Profile

Corporate Profile

...assay marketed for compound testing and target validation Founded: 1998 by Warren Hoeffler Corporate partners: Cellmed...
BioCentury | Apr 22, 2002
Emerging Company Profile

Xgene: High throughput skin

...tests using the 96-well format, an application for which competing products are approved in Europe. CellMed...
BioCentury | Mar 11, 2002
Company News

Xgene Corp. sales and marketing update

...high throughput compound testing and target validation studies. The product is marketed in Germany by CellMed...
Items per page:
1 - 9 of 9
BioCentury | Dec 5, 2011
Company News

Cellmed management update

Cellmed Research GmbH , Krems, Austria Business: Biomanufacturing, Supply/Service Hired: Karl Krista as CEO WIR Staff...
BioCentury | Mar 15, 2010
Company News

Biocompatibles, Celsion, Cortius B.V., Glycostem Therapeutics, ISA Pharmaceuticals, IQ Corp. B.V., Percuros B.V., Biomedical Materials, Center for Translational

...progenitor cells. Erasmus will work with University Medical Center Utrecht (UMCU), Biocompatibles and the company's CellMed...
BioCentury | Feb 22, 2010
Clinical News

CM-3: Phase I started

...Biocompatibles' CellMed AG unit began a double-blind, placebo-controlled, German Phase I trial to evaluate single ascending...
BioCentury | Dec 14, 2009
Clinical News

CM-3: Phase I start

...Next month, Biocompatibles' CellMed unit will begin a Phase I trial. AstraZeneca plc (LSE:AZN; NYSE:AZN, London...
BioCentury | Jan 14, 2008
Clinical News

Doxorubicin Drug Eluting Bead regulatory update

...The EC granted Orphan Drug designation for doxorubicin hydrochloride drug eluting beads from CellMed AG, a...
BioCentury | Jan 14, 2008
Clinical News

Irinotecan Drug Eluting Bead regulatory update

...The EC granted Orphan Drug designation for irinotecan hydrochloride drug eluting beads from CellMed AG, a...
BioCentury | Apr 22, 2002
Emerging Company Profile

Corporate Profile

...assay marketed for compound testing and target validation Founded: 1998 by Warren Hoeffler Corporate partners: Cellmed...
BioCentury | Apr 22, 2002
Emerging Company Profile

Xgene: High throughput skin

...tests using the 96-well format, an application for which competing products are approved in Europe. CellMed...
BioCentury | Mar 11, 2002
Company News

Xgene Corp. sales and marketing update

...high throughput compound testing and target validation studies. The product is marketed in Germany by CellMed...
Items per page:
1 - 9 of 9